In the first genome-wide association study (GWAS) of leprosy and the largest GWAS on an infectious disease, scientists at the Genome Institute of Singapore (GIS) and 26 institutes in China identified seven genes that increase an individual's susceptibility to leprosy.
The discovery of these genes, reported in the 16 Dec. 2009 New England Journal of Medicine, highlights the important role of the innate immune response in the development of leprosy, said the scientists, who analyzed over 10,000 samples from leprosy patients and healthy controls in China.
"Though leprosy is not common, the discoveries have significant ramifications for chronic infectious disorders and for host-pathogen interactions in other more prevalent mycobacterial diseases such as tuberculosis, said Edison Liu, M.D., Executive Director of GIS, one of the research institutes sponsored by Singapore's Agency for Science, Technology and Research (A*STAR).
"This study represents one of the largest and best organized studies of the host genetics in infectious diseases published," added Dr. Liu.
An immunologist who was not one of the authors of the NEJM paper, Tom H. M. Ottenhoff, M.D., Ph.D., of Leiden University Medical Center in The Netherlands, said,
"This is a very impressive study, which uncovers entirely new genes that control susceptibility to leprosy and perhaps also other related diseases. A great asset is that the study underpins the genetic data with plausible functional biology experimentation, which is not often seen."
Dr. Ottenhoff is Professor in Immunology, Head group Immunology and Immunogenetics of Bacterial Infectious Diseases, at Leiden University Medical Center.
The seven genes associated with susceptibility to leprosy are: CCDC122, C13orf31, NOD2, TNFSF15, HLA-DR, RIPK2 and LRRK2.
"This is a very significant find, and one that can only be achieved through large-scale genetic studies, with close collaborative efforts among multi-disciplinary research groups, often across different countries," said Jianjun Liu, Ph.D., Human Genetics Group Leader at the GIS.
"The discovery of these genes is a major breakthrough for research in leprosy and infectious diseases in general, and will be significant in the early diagnosis and development of new treatments," added Dr. Liu.
In addition to Dr. Liu, the leaders of the GWAS on leprosy included: Fu-Ren Zhang, M.D., Ph.D., of Shandong Provincial Institute of Dermatology and Venereology, and Xue-jun Zhang, M.D., Ph.D., of Institute of Dermatology and Department of Dermatology at No.1 Hospital, Anhui Medical University, China.
GIS Executive Director Dr. Liu noted, , "This is a continuation of a number of deep collaborative studies between the GIS and Chinese scientists in using population sciences to uncover genetic modifiers of human disease. The strength of Chinese clinical sciences and of Singapore's targeted genomic capabilities makes a powerful scientific combination. The key to this collaboration and one that was recently published on the genetics of Asian migration is that the studies were initiated and executed by Asian partners acting as equals. Hopefully, this will initiate a new phase of cooperation between historically competing Asian countries whose primary links have been with western communities."
Leprosy, a chronic infectious disease caused by the bacterium Mycobacterium leprae (M. leprae), mainly affects skin and peripheral nerves and may lead to irreversible disabilities. Although it has been largely eliminated in developed countries, leprosy is still a major public health problem in many developing countries, particularly in tropic and sub-tropic regions. According to the World Health Organization, 254,525 new cases of leprosy were diagnosed in 2007. Although many people are potentially exposed to M. leprae in endemic regions, only a small minority will be infected and will develop clinically overt leprosy, suggesting that only some individuals are susceptible to this disease.
Because M. leprae cannot be cultured in the laboratory, and because it only infects humans and the Armadillo, research and thus the biological understanding of leprosy are very limited. The discovery of the seven susceptibility genes not only improves scientists' understanding about genetic susceptibility to the disease, but also may stimulate additional biological and clinical research to reveal the mechanism of leprosy development.
Authors of the NEJM paper, "Genomewide association study of leprosy":
Fu-Ren Zhang, M.D., Ph.D., Wei Huang, Ph.D., Shu-Min Chen, M.D., Ph.D., Liang-Dan Sun, M.D., Ph.D., Hong Liu, M.D., Yi Li, Ph.D., Yong Cui, M.D., Ph.D., Xiao-Xiao Yan, M.D., Hai-Tao Yang, M.D., Rong-De Yang, M.D., Tong-Sheng Chu, M.D., Chi Zhang, M.D., Lin Zhang, M.D., Jian-Wen Han, M.D., Gong-Qi Yu, B.S., Cheng Quan, M.D., Yong-Xiang Yu, B.S., Zheng Zhang, M.D., Ben-Qing Shi, M.D., Lian-Hua Zhang, M.D., Hui Cheng, M.D., Chang-Yuan Wang, M.D., Yan Lin, M.D., Hou-Feng Zheng, M.D., Xi-An Fu, M.D., Xian-Bo Zuo, M.S., Qiang Wang, M.D., Heng Long, M.D., Yi-Ping Sun, M.D., Yi-Lin Cheng, M.S., Hong-Qing Tian, M.D., Fu-Sheng Zhou, B.S., Hua-Xu Liu, M.D., Ph.D., Wen-Sheng Lu, M.D., Su-Min He, M.D., Wen-Li Du, B.S., Min Shen, B.S., Qi-Yi Jin, B.S., Ying Wang, Ph.D., Hui-Qi Low, B.S., Tantoso Erwin, B.S., Ning-Han Yang, B.S., Jin-Yong Li, M.D., Xin Zhao, M.D., Yue-Lin Jiao, M.D., Li-Guo Mao, M.D., Gang Yin, M.D., Zhen-Xia Jiang, M.D., Xiao-Dong Wang, M.D., Jing-Ping Yu, M.D., Zong-Hou Hu, M.D., Cui-Hua Gong, M.D., Yu-Qiang Liu, M.D., Rui-Yu Liu, M.D., De-Min Wang, M.D., Dong Wei, M.D., Jin-Xian Liu, M.D., Wei-Kun Cao, M.D., Hong-Zhong Cao, M.D., Yong-Ping Li, M.D., Wei-Guo Yan, M.D., Shi-Yu Wei, M.D., Kui-Jun Wang, M.D., Martin L. Hibberd, Ph.D., Sen Yang, M.D., Ph.D., Xue-Jun Zhang, M.D., Ph.D., and Jian-Jun Liu, Ph.D.
The authors' affiliations are as follows: Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Science, Jinan, Shandong, China (F.R.Z., S.M.C., H.L., X.X.Y., T.S.C., L.Z., G.Q.Y., Y.X.Y., B.Q.S., C.Y.W., Y.L., X.A.F., Y.P.S., H.Q.T., H.X.L., W.L.D., J.J.L.); Institute of Dermatology and Department of Dermatology at No.1 Hospital, Anhui Medical University, Hefei, Anhui, China; The Key Laboratory of Gene Resource Utilization for Severe Diseases, Ministry of Education and Anhui Province, Hefei, Anhui, China (L.D.S., Y.C., S.Y., C.Z., J.W.H., C.Q., Z.Z., H.C., H.F.Z., X.B.Z., Y.L.C., F.S.Z., W.S.L., S.M.H., X.J.Z. J.J.L.); Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China (H.W., M.S., Q.Y.J., Y.W.); Genome Institute of Singapore, Singapore (J.J.L., Y.L., H.Q.L., T.E., N.Y., M.L.H.); Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China (Y.H.T., L.H.Z.); Wenshan Institute of Dermatology, Wenshan, Yunnan, China (R.D.Y., H.L.); Anhui Provincial Institute of Dermatology, Hefei, Anhui, China (Q.W.); Weifang Institute of Dermatology, Weifang, Shandong, China (J.Y.L.); Linyi Institute of Dermatology, Linyi, Shandong, China (X.Z.); Yantai Institute of Dermatology, Yantai, Shandong, China (Y.L.J.) Jining Institute of Dermatology, Jining, Shandong, China (L.G..M.); Zaozhuang Institute of Dermatology, Zaozhuang, Shandong, China (G.Y.); Qingdao Center for Disease Control and Prevention, Qingdao, Shandong, China (Z.X.J.); Jinan Institute of Dermatology, Jinan, Shandong, China (X.D.W.); Weihai Center for Disease Control and Prevention (J.P.Y.); Rizhao Institute of Dermatology (Z.H.H); Zibo Center for Disease Control and Prevention (C.H.G.); Qixia County Skin Disease Control Station (Y.Q.L.); Linqu County Skin Disease Control Station (R.Y.L.); Zhucheng County Skin Disease Control Station (D.M.W.); Zoucheng County Skin Disease Control Station (D.W.); Linshu County Skin Disease Control Station (J.X.L.); Feixian County Skin Disease Control Station (W.K.C.); Sishui County Skin Disease Control Station (H.C.C.); Tengzhou County Skin Disease Control Station (Y.P.L); Shouguang Skin Disease Control Station (W.G.Y). Laixi County Skin Disease Control Station (S.Y.W.); Pingdu County Skin Disease Control Station (K.J.W).
Correspondence: Dr. Jianjun Liu, Genome Institute of Singapore
Email: liuj3@gis.a-star.edu.sg; Tel: +65 68088088.
For press enquiries, please contact:
Genome Institute of Singapore:
Winnie Serah Lim
Office of Corporate Communications
Tel: (65) 6808 8013
(65) 9730 7884
Email: limcp2@gis.a-star.edu.sg
Genome Institute of Singapore:
www.gis.a-star.edu.sg
The Genome Institute of Singapore (GIS) is a member of the Agency for Science, Technology and Research (A*STAR). It is a national initiative with a global vision that seeks to use genomic sciences to improve public health and public prosperity. Established in 2001 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards the goal of individualized medicine. The key research areas at the GIS include Systems Biology, Stem Cell & Developmental Biology, Cancer Biology & Pharmacology, Human Genetics, Infectious Diseases, Genomic Technologies, and Computational & Mathematical Biology. The genomics infrastructure at the GIS is utilized to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact.
Agency for Science, Technology and Research (A*STAR): www.a-star.edu.sg
The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences, and physical sciences and engineering research institutes, and seven consortia & centre, which are located in Biopolis and Fusionopolis, as well as their immediate vicinity.
A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, hospitals, research centres, and with other local and international partners.
Journal
New England Journal of Medicine